511 related articles for article (PubMed ID: 12566596)
1. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months.
Blesa R; Davidson M; Kurz A; Reichman W; van Baelen B; Schwalen S
Dement Geriatr Cogn Disord; 2003; 15(2):79-87. PubMed ID: 12566596
[TBL] [Abstract][Full Text] [Related]
2. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months.
Wilkinson DG; Hock C; Farlow M; van Baelen B; Schwalen S
Int J Clin Pract; 2002 Sep; 56(7):509-14. PubMed ID: 12296613
[TBL] [Abstract][Full Text] [Related]
3. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
Aronson S; Van Baelen B; Kavanagh S; Schwalen S
Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
[TBL] [Abstract][Full Text] [Related]
4. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
5. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
6. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
7. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
8. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
9. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia.
Erkinjuntti T; Kurz A; Small GW; Bullock R; Lilienfeld S; Damaraju CV;
Clin Ther; 2003 Jun; 25(6):1765-82. PubMed ID: 12860497
[TBL] [Abstract][Full Text] [Related]
10. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial.
Raskind MA; Peskind ER; Truyen L; Kershaw P; Damaraju CV
Arch Neurol; 2004 Feb; 61(2):252-6. PubMed ID: 14967774
[TBL] [Abstract][Full Text] [Related]
11. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
12. Galantamine: additional benefits to patients with Alzheimer's disease.
Lilienfeld S; Parys W
Dement Geriatr Cogn Disord; 2000 Sep; 11 Suppl 1():19-27. PubMed ID: 10971048
[TBL] [Abstract][Full Text] [Related]
13. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial.
Rockwood K; Fay S; Song X; MacKnight C; Gorman M;
CMAJ; 2006 Apr; 174(8):1099-105. PubMed ID: 16554498
[TBL] [Abstract][Full Text] [Related]
14. Maintaining cognitive function in Alzheimer disease: how effective are current treatments?
Tariot PN
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S26-33. PubMed ID: 11669506
[TBL] [Abstract][Full Text] [Related]
15. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
16. Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease.
Marcusson J; Bullock R; Gauthier S; Kurz A; Schwalen S
Alzheimer Dis Assoc Disord; 2003; 17 Suppl 3():S86-91. PubMed ID: 14512822
[TBL] [Abstract][Full Text] [Related]
17. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.
Raskind MA; Peskind ER; Wessel T; Yuan W
Neurology; 2000 Jun; 54(12):2261-8. PubMed ID: 10881250
[TBL] [Abstract][Full Text] [Related]
18. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of galantamine treatment in patients with Alzheimer disease.
Lyketsos CG; Reichman WE; Kershaw P; Zhu Y
Am J Geriatr Psychiatry; 2004; 12(5):473-82. PubMed ID: 15353385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
